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There is a need to identify genetic mediators of solid-tumor cancers, such as prostate cancer, where
invasion and distant metastases determine the clinical outcome of the disease. Whole-genome
expression profiling offers promise in this regard, but can be complicated by the challenge of
identifying the genes affected by a condition from the hundreds to thousands of genes that exhibit
changes in expression. Here, we show that reverse-engineered gene networks can be combined with
expression profiles to compute the likelihood that genes and associated pathways are mediators of
a disease. We apply our method to non-recurrent primary and metastatic prostate cancer data, and
identify the androgen receptor gene (AR) among the top genetic mediators and the AR pathway as a
highly enriched pathway for metastatic prostate cancer. These results were not obtained on the basis
of expression change alone. We further demonstrate that the AR gene, in the context of the network,
can be used as a marker to detect the aggressiveness of primary prostate cancers. This work shows
that a network biology approach can be used advantageously to identify the genetic mediators and
mediating pathways associated with a disease.
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Introduction
Since the introduction of microarrays, there has been
considerable interest in using whole-genome expression
profiling to gain insight into cancer and to identify key genetic
mediators. Although there has been some success in this
regard, many efforts have been complicated by the fact that it is
difficult with expression data to identify the genes affected by a
condition from the hundreds to thousands of genes that exhibit
changes in expression. In this work, we show that a network
biology approach can be used to take on this challenge.
Specifically, we show that reverse-engineered gene networks
can be combined with expression profiles to identify the
genetic mediators and mediating pathways associated with
prostate cancer.
We used an approach called mode-of-action by network
identification (MNI), which has previously been validated as
a means to identify the targets and associated pathways of
compounds (di Bernardo et al, 2005). The MNI algorithm
operates in two phases (Figure 1). In phase one, a network
model of regulatory interactions is reverse engineered with a
diverse training set of whole-genome expression profiles. In
phase two, the network is used as a filter to determine the
genes affected by a condition of interest, for example, a disease
(Figure 1). The highest ranked mediator genes, ranked by a
Z-statistic, are those whose expression is most inconsistent
with the model, and this inconsistency is attributed to the
external influence of the condition on those genes. Genes
implicated in the advancement as well as suppression of a
disease are equally likely to be identified as significant genetic
mediators by the MNI algorithm (see Supplementary informa-
tion). The MNI algorithm requires that the training expression
profiles influence a diversity of cell functions. As a training set,
we used a total of 1144 microarray expression profiles based on
13 projects spanning seven different cancer types: adrenal,
brain, breast, leukemia, lung, prostate and thyroid (Materials
and methods). As test conditions, we used expression profiles
of 14 non-recurrent primary and nine distant metastatic
prostate cancer samples (LaTulippe et al, 2002). Each of these
samples was queried against the reconstructed network, and
the resulting potential genetic mediators in each case were
ranked according to the Z-score statistic. A characteristic list
of 100 genes for the non-recurrent primary and metastatic
prostate cancer groups, respectively, was obtained by aver-
aging the Z-scores across all samples.
Normal prostate and early-stage prostate cancers depend on
androgens for growth and survival. As the cancer advances
and metastasizes, it becomes dominated by cells that
proliferate and survive independent of androgens; this effect
is provoked by androgen ablation therapy (Taplin et al, 1995;
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Abate-Shen and Shen, 2000; Feldman and Feldman, 2001;
Navarro et al, 2002; Balaji et al, 2004; Shultz, 2005). Androgen
independence is manifested in several ways. In some cases,
sensitivity to low levels of androgen is increased by amplifica-
tion, mutations and/or elevated levels or broadened specificity
of co-activators of the androgen receptors. In other cases,
activation of androgen receptors occurs in the absence of
androgens due to crosstalk via other signaling pathways
(Hobisch et al, 1995; Taplin et al, 1995; Abate-Shen and Shen,
2000; Feldman and Feldman, 2001; Navarro et al, 2002; Balaji
et al, 2004; Shultz, 2005). It has been shown that almost all
metastatic prostate cancers shift to an androgen-independent
state (Abate-Shen and Shen, 2000; Navarro et al, 2002; Balaji
et al, 2004). After anti-androgenic treatment, primary prostate
cancers can also shift to an androgen-independent state and
become recurrent (Abate-Shen and Shen, 2000; Navarro et al,
2002). In order to differentiate between the two groups
optimally, we chose to analyze nine advanced-stage metastatic
prostate cancer samples and 14 non-recurrent primary
prostate cancer samples from LaTulippe et al (2002) (primary
prostate cancer samples remained non-recurrent after a mean
follow-up of 42 months).
The above points led us to hypothesize that the AR gene
would be among the top genetic mediators identified by the
MNI algorithm for the metastatic prostate cancer group only,
indicative of its key role in androgen-independent metastatic
prostate cancer. Moreover, because having amplifications,
mutations and increased specificity for AR in androgen-
independent prostate cancer raises the possibility that down-
stream genes in the AR pathway are also involved in the
progression and metastasis of the disease, we further
hypothesized that the AR signaling pathway would be highly
enriched in the metastatic prostate cancer group.
Results and discussion
The list of the top 100 potential genetic mediators for non-
recurrent primary and metastatic prostate cancer groups along
with their expression change rankings is given in Supplemen-
tary Table 1.
The MNI algorithm identified the AR gene among the top
genetic mediators in the metastatic prostate cancer group but
not in the non-recurrent primary prostate group. We next
subjected the 100 highest ranked genes in non-recurrent
primary and metastatic prostate cancer groups to enrichment
analysis for the AR signaling pathway. We found that the list
of the top 100 genes for the metastatic prostate cancer was
enriched (P¼1.5108) for the AR signaling pathway, in
contrast to that for non-recurrent primary prostate cancer,
which was not enriched (Figure 2). These results, which are
consistent with our hypotheses, imply that the AR gene and
the AR pathway are mediators of prostate cancer progression
and metastasis.
Figure 2 includes the 20 genes transcriptionally regulated in
the AR signaling pathway, identified among the top mediators
for the metastatic prostate cancer group. It is thought that
these genes may play a role in the acquisition of androgen-
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Figure 1 A schematic diagram of the MNI method as applied to identify genetic mediators for non-recurrent primary and metastatic prostate cancer. In phase 1,
microarray data obtained from a variety of cancer cell lines or patient tissue samples are used by the MNI algorithm to infer a model of regulatory interactions between
genes (blue-filled circles indicate genes, arrows indicate regulatory influences). In phase 2, test condition expression data are filtered using the reconstructed network to
distinguish the genes affected by a condition (red-filled circles) from the hundreds to thousands of genes that exhibit changes in expression. This procedure is applied to
non-recurrent primary prostate cancer and metastatic prostate cancer samples to identify genetic mediators.
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independent growth (Velasco et al, 2004). Among these 20
genes, six are well-known androgen-regulated genes (ARG)—
AR, PSMA, HOXB13, NKX3-1, CITED2, UGT2B15 (Nelson
et al, 2002; Velasco et al, 2004)—which have been shown to
mediate metastatic disease progression. For example, PSMA
(also known as FOLH1), prostate-specific membrane antigen
1, is used as a diagnostic and prognostic indicator for prostate
cancer and is associated with prostate cancer aggressiveness
and metastasis (Burger et al, 2002; Schmittgen et al, 2003;
Kinoshita et al, 2005). HOXB13, homeobox B13, has been
implicated in progression and metastasis in prostate cancer
(Jung et al, 2004; Edwards et al, 2005; Zhao et al, 2005) and
found to function as an AR repressor, modulating AR signaling
(Jung et al, 2004). Loss of NKX3-1 expression, a homeodomain
transcription factor, is found in 60–80% of human prostate
carcinomas (Bhatia-Gaur et al, 1999) and has been associated
with advanced prostate cancer and metastasis (Bowen, 2000).
It has also been shown that a majority of Nkx3.1þ /;Ptenþ /
mice develop invasive adenocarcinoma in the lymph nodes
(Abate-Shen et al, 2003). CITED2 is known to play a crucial
role in the control of tumor hypoxia, which is associated with
metastatic progression (Aprelikova et al, 2006). UGT2B15,
UDP glucuronosyltransferase 2 family polypeptide B15, a
steroid-metabolizing protein, has been found to be differen-
tially expressed in androgen-independent bone marrow
metastases following androgen ablation therapy (Guillemette
et al, 1997; Hum et al, 1999; Stanbrough et al, 2006). We
discuss the clinical significance of some of the other top
mediators in Supplementary information.
We next focused on GO-annotated pathways that were
significantly overrepresented among the highly ranked genetic
mediators. For our analysis, we subjected the 100 highest
ranked genes identified by MNI in the metastatic and non-
recurrent primary prostate cancer groups, respectively, to
pathway analysis based on the GO biological process annota-
tions obtained from Affymetrix.
The significantly enriched GO-annotated pathways for
metastatic and non-recurrent primary prostate cancer based
on MNI analysis are shown in Figure 2. These pathways fall
into two categories, which are well-established processes
identified as hallmarks of all cancers—metabolism and
immune response (Weinberg and Hanahan, 2000). As malig-
nant tumors consist of dividing cells, cancerous tissues have
a high metabolic activity. The metabolism pathway is highly
enriched in both non-recurrent primary and metastatic
prostate cancer groups (Figure 2). Transport, indicative of
high metabolism, is also significantly enriched in the meta-
static prostate cancer group. The immune response is the main
defense against cancer, and MNI successfully identifies the
inflammatory response, the immune system-related biological
pathway, in the metastatic prostate cancer group (Figure 2).
Interestingly, some AR pathway genes are also part of the
enriched GO-annotated pathways. Specifically, GSTA2, ALD-
H1A3 and UGTB15 in the metabolism pathway, ORM1 and AR
Non-recurrent primary prostate cancer
Expression change analysis
Metastatic prostate cancer
AR pathway (1.5e–08)
ORM1, MCCC2, AR, GSTA2, PSMA, PAM,  NUCB2, 
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    NKX3-1, CITED2, SORD, CMKOR1, UGT2B15, 
                     JAG1, GATA2, PPP1CB
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ORM1, CCL18, C4A, ALOX5AP, LY96, CCL13
GO: muscle development (2.7e–12)
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                      ALCAM, RHOB, DDR2
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               DPP4, WFDC2
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Figure 2 Significantly enriched pathways among top 100 genetic mediators identified by MNI and expression change alone, respectively, in non-recurrent primary and
metastatic prostate cancer groups.
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in the transport pathway and ORM1 in the inflammatory
response are all androgen-responsive genes. This raises the
possibility that the metabolism, transport and inflammatory
response pathways in the metastatic prostate cancer group
may be enriched as a result of increased activity of androgen-
responsive genes in the AR signaling pathway.
In order to assess the relative merits of using MNI, a
network-based approach, we performed pathway enrichment
analysis on the top 100 ranked genes obtained by expression
change alone and by using GSEA, a gene set enrichment tool
(http://www.broad.mit.edu/gsea/). GO biological process
pathway enrichment analysis, based on expression change
alone, identified proteolysis and peptidolysis as a highly
enriched pathway in the non-recurrent primary prostate
cancer group and muscle development, muscle contraction
and cell-adhesion pathways in the metastatic prostate cancer
group (Figure 2). GO biological process pathway enrichment
analysis using GSEA did not identify any significantly enriched
pathways (Materials and methods). Compared to expression
change alone, MNI failed to identify the cell-adhesion path-
way, which is important in the spread and invasion of the
cancer, as a highly enriched pathway. However, MNI was
successful in eliminating false positives such as muscle
contraction and muscle development pathways in the meta-
static prostate cancer group. MNI’s advantage was most
apparent in predicting the AR signaling pathway as a mediator
for metastatic prostate cancer. Neither expression change
alone nor GSEA identified AR signaling as a highly enriched
pathway. These analyses reveal the benefit of our network-
based approach in that it highly ranks genes whose expression
is not significantly different from normal and do not have
coordinated expression, but which are relevant genetic
mediators, such as the AR signaling pathway genes in the
metastatic prostate cancer group.
Motivated by the above findings and the ability of our
approach to differentiate between non-recurrent primary and
metastatic prostate cancer, we next applied the MNI algorithm
to nine recurrent primary prostate cancer samples (which
had recurred within a mean follow-up of 42 months) from
LaTulippe et al (2002). We hypothesized that the MNI ranking
of the AR gene would move up as an indication of the
aggressiveness of the disease. Consistent with this hypothesis,
MNI ranked the AR gene 970, 155 and 9 for the non-recurrent
primary, recurrent primary and metastatic prostate cancer
groups, respectively (Figure 3). This finding suggests that the
AR gene, in the context of the reverse-engineered network, can
be used as a marker for detecting the aggressiveness of primary
prostate cancers. Interestingly, expression change alone
ranked the AR gene 641, 668 and 207 in the respective groups
(Figure 3), indicating that expression change alone is incap-
able of capturing the differential involvement of the AR gene
in recurrent and non-recurrent primary prostate cancers.
In this study, we showed that a network biology approach
that filters expression profiles through a reverse-engineered
gene network can be used to identify the genetic mediators
and mediating pathways of a disease. Specifically, we identified
key genetic mediators and pathways that have been implicated
in the initiation, advancement and invasion of prostate cancer.
Our approach extends the utility of whole-genome expression
profiling, and may be useful as a predictive tool for identifying
novel genetic mediators for other cancers, such as breast
cancer and leukemia. Network-based techniques (Gardner
et al, 2003; Barabasi and Oltvai, 2004; Basso et al, 2005; Segal
et al, 2005; Yeang et al, 2005) may also prove useful for
providing biological insight into the etiology and progression
of other diseases.
Materials and methods
Microarray data were collected from five publicly available databases:
the NIH Gene Expression Omnibus (GSE349, GSE1431, GSE1923,
GSE3960), Oncomine (Giordano_Adrenal, Nutt_Brain, Huang_Breast,
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Figure 3 AR gene rankings based on MNI and expression change alone. The MNI ranking of the AR gene moves up as an indication of the aggressiveness of the
disease. Expression change alone is unable to capture the differential involvement of the AR gene in the recurrent and non-recurrent primary prostate cancer groups.
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LaTulippe_Prostate, Huang_Thyroid), EBI ArrayExpress (MEXP-441),
Broad Institute Cancer Datasets (Bhatacharjee et al—Lung, Singh
et al—Prostate) and the St Jude Research Datasets (Yeoh et al—
Leukemia). The collected data were from experiments conducted on
Affymetrix GeneChip Human Genome 95A or 95Av2; the combined
microarrays have 12 600 overlapping probe sets. A total of 1144
experiments were collected based on 13 projects spanning seven
different cancer types: adrenal, brain, breast, leukemia, lung, prostate
and thyroid. CEL (cell intensity) files were processed individually for
each project using RMAExpress. Each experiment in the data matrix
was normalized by its mean to account for experimental variation
between labs, and each probe set was normalized by its average across
all experiments to obtain expression changes relative to a baseline. The
MNI algorithm takes in as input the log-transformed expression ratios
and standard errors. The data were log 2-transformed before being
input to the MNI algorithm. As there were no repeated experiments in
the collected set of microarray data, the standard error was set to 1.0
for all experiments and probe sets.
The MNI algorithm, which is described in detail in Supplementary
information, takes as a training set all of the expression profiles except
user-specified test profiles. We used as test profiles data from
LaTulippe et al (2002), which includes samples from 14 non-recurrent
primary prostate cancers, nine recurrent primary prostate cancers and
nine metastatic prostate cancers located in the lymph node, bone, lung
or soft tissue. The MNI algorithm was configured to output the top 200
mediators for each sample, together with the associated Z-scores for
those probe sets. We set to zero the Z-score for probe sets that were not
within the list of the top 200 probe sets identified as mediators for
a given sample. To identify a characteristic list of genes within each
group (i.e., non-recurrent primary, recurrent primary and metastatic
prostate cancer), the Z-scores across samples and across probe sets for
corresponding genes were averaged and ranked. The top 100 genes
within that list were chosen to be reported as significant genetic
mediators. A higher average Z-score is an indication of higher number
of occurrences of a gene on the lists generated by the MNI algorithm
in each group.
We compared the MNI rankings with those obtained using purely
expression values. To make this comparison, we scored transcripts
based on their differential expression from normal prostate tissue
samples. Characteristic normal, non-recurrent primary, recurrent
primary and metastatic expression profiles were created by averaging
the normalized transcript expression for each of the experiments
in those respective categories from LaTulippe et al (2002). The non-
recurrent primary, recurrent primary and metastatic characteristic
profiles were then divided by the normal profiles to obtain expression
ratios. Ratios that were less than 1 were inverted to equally weight up-
and downregulation. Expression rankings were obtained for each
transcript using these two lists.
Pathway enrichment was performed on the top 100 genetic
mediators identified for the non-recurrent primary and metastatic
prostate cancer cases. The pathway annotations were based on the GO
biological process annotations from Affymetrix for the HU95A and
HU95Av2 chips. AR signaling pathway transcriptionally regulated
genes were obtained from the NetPath database (http://www.netpath.
org/). P-values for the pathway enrichment were calculated based
on a hypergeometric distribution. We report significant pathway
enrichments for groups with at least four members and P-
valuesp0.01. GSEA (http://www.broad.mit.edu/gsea/) pathway
enrichment was performed on the AR signaling pathway and all
GO-annotated pathways. We used the GSEA-suggested threshold
cutoff FDR¼0.25.
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (www.nature.com/msb).
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